Skip to main content

Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation

Abstract

Introduction

The objective of this study was to compare the risk of stroke in atrial fibrillation (AF) with adherent use of oral anticoagulation (OAC), non-adherent use, and non-use of OAC.

Methods

Using 2013–2016 Medicare claims data, we identified patients newly diagnosed with AF in 2014–2015 and collected prescriptions filled for OAC in the 12 months after AF diagnosis (n = 39,272). We categorized participants each day into three time-dependent exposures: adherent use (≥ 80% of the previous 30 days covered with OAC), non-adherent use (0–80% covered with OAC), and non-use (0%). We constructed Cox proportional hazards models to estimate the association between time-dependent exposures and time to stroke, adjusting for demographics and clinical characteristics.

Results

The sample included 39,272 patients. Study participants spent 35.0% of the follow-up period in the adherent use exposure category, 10.9% in the non-adherent category, and 54.0% in the non-use category. OAC adherent use [hazard ratio (HR) 0.62; 95% confidence interval (CI) 0.52–0.74] and non-adherent use (HR 0.74; 95% CI 0.57–0.95) were associated with lower hazards of stroke than non-use. Adherent use of DOAC (HR 0.54; 95% CI 0.42–0.69) and warfarin (HR 0.70; 95% CI 0.56–0.89) was associated with lower risk of stroke than non-use, but the risk of stroke did not statistically differ between DOAC and warfarin adherent use (HR 0.77; 95% CI 0.56–1.04).

Discussion

Although adherence to OAC reduces stroke risk by nearly 40%, newly diagnosed AF patients in Medicare adhere to OAC on average only one third of the first year after AF diagnosis.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32(3):803–8.

    CAS  Article  Google Scholar 

  2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.

    Article  Google Scholar 

  3. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-645.e634.

    Article  Google Scholar 

  4. Lang K, Bozkaya D, Patel AA, et al. Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis. BMC Health Serv Res. 2014;14:329.

    Article  Google Scholar 

  5. Kakkar AK, Mueller I, Bassand J-P, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-19.e11.

    Article  Google Scholar 

  6. Patel AA, Lennert B, Macomson B, et al. Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation. Am Health Drug Benefits. 2012;5(5):291–8.

    PubMed  PubMed Central  Google Scholar 

  7. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538–43.

    CAS  Article  Google Scholar 

  8. Ogilvie IM, Welner SA, Cowell W, Lip GY. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol. 2011;108(1):151–61.

    Article  Google Scholar 

  9. Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183–200.

    CAS  Article  Google Scholar 

  10. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017;120(10):1813–9.

    CAS  Article  Google Scholar 

  11. Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation in stroke prevention in atrial fibrillation. Stroke. 48:2289–2291.

  12. Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–84.

    CAS  Article  Google Scholar 

  13. Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55–62.

    Article  Google Scholar 

  14. Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016;5(2).

  15. Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the Veterans Health Administration. BMC Cardiovasc Disorders. 2017;17(1):236. https://doi.org/10.1186/s12872-017-0671-6.

    Article  Google Scholar 

  16. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–9.

    Article  Google Scholar 

  17. Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin. 2015;31(10):1889–95. https://doi.org/10.1185/03007995.2015.1077213.

    CAS  Article  PubMed  Google Scholar 

  18. Center for Medicare and Medicaid Services Chronic Conditions Data Warehouse. 27 Chronic Condition Algorithm. https://www.ccwdata.org/cs/groups/public/documents/document/ccw_condition_categories.pdf Accessed April 26, 2017.

  19. Kumamaru H, Judd SE, Curtis JR, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with Medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7(4):611–9.

    Article  Google Scholar 

  20. Lo-Ciganic WH, Donohue JM, Jones BL, et al. Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program. J Gen Intern Med. 2016;31(9):1052–60. https://doi.org/10.1007/s11606-016-3747-6.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lo-Ciganic WH, Donohue JM, Thorpe JM, et al. Using machine learning to examine medication adherence thresholds and risk of hospitalization. Med Care. 2015;53(8):720–8.

    Article  Google Scholar 

  22. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725. https://doi.org/10.1161/jaha.116.003725.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6(5):567–74.

    Article  Google Scholar 

  24. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

    Article  Google Scholar 

  25. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.

    Article  Google Scholar 

  26. Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48(8):2142–9.

    CAS  Article  Google Scholar 

  27. Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014;127(11):1075-1082.e1071.

    Article  Google Scholar 

  28. Hernandez I, Zhang Y, Brooks MM, Chin PK, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017;48(1):159–66.

    CAS  Article  Google Scholar 

  29. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.

    Article  Google Scholar 

  30. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.

    Article  Google Scholar 

  31. Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D data. Am J Cardiovasc Drug. 2017;17(1):37–47.

    CAS  Article  Google Scholar 

  32. Gray M, Saba S, Zhang Y, Hernandez I. Outcomes of atrial fibrillation patients newly recommended for oral anticoagulation under the 2014 AHA/ACC/HRS guideline. J Am Heart Assn 7(1):e007881.

  33. Hernandez I, Zhang Y, Saba S. Effectiveness and safety of direct oral anticoagulants and warfarin, stratified by stroke risk in patients with atrial fibrillation. Am J Cardiol. 2018;122(1):69–75.

    CAS  Article  Google Scholar 

  34. Peterson ED, Pokorney SD. New treatment options fail to close the anticoagulation gap in atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2485–7.

    Article  Google Scholar 

  35. Hess PL, Mirro MJ, Diener HC, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J. 2014;168(3):239-247.e231.

    Article  Google Scholar 

  36. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14 Suppl):S451–8.

    PubMed  Google Scholar 

  37. Patel AA, Ogden K, Veerman M, Mody SH, Nelson WW, Neil N. The economic burden to Medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. Popul Health Manag. 2014;17(3):159–65.

    Article  Google Scholar 

  38. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546–50.

    Article  Google Scholar 

  39. Andersohn F, Willich SN. The healthy adherer effect. Arch Intern Med. 2009;169(17):1633–8.

    Article  Google Scholar 

Download references

Acknowledgments

This work represents the opinions of the authors alone and does not necessarily represent the views of the Department of Veterans Affairs or the United States Government.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Inmaculada Hernandez.

Ethics declarations

Funding

This work was funded by the National Heart, Lung and Blood Institute (Grant number K01HL142847).

Conflict of interest

Saba has received research support from Boston Scientific. Hernandez has received advisory board fees from Pfizer. He, Brooks and Gellad declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 54 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hernandez, I., He, M., Brooks, M.M. et al. Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. Am J Cardiovasc Drugs 20, 199–207 (2020). https://doi.org/10.1007/s40256-019-00371-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-019-00371-3